Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2018-10-31

FDA Approved: BUPRENORPHINE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)

View source ↗

Summary

FDA approved a supplemental application for buprenorphine from Hikma Pharmaceuticals USA Inc., granting approval for changes to an already-approved product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Buprenorphine (generic) (BUPRENORPHINE)

Snippet

SUPPL AP for BUPRENORPHINE (BUPRENORPHINE)